Canada · Delayed Price · Currency is CAD Pharmadrug Statistics
Total Valuation
Pharmadrug has a market cap or net worth of CAD 1.62 million. The enterprise value is 3.17 million.
| Market Cap | 1.62M |
| Enterprise Value | 3.17M |
Important Dates
The next estimated earnings date is Monday, November 3, 2025.
| Earnings Date | Nov 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharmadrug has 108.23 million shares outstanding. The number of shares has increased by 33.39% in one year.
| Current Share Class | 108.23M |
| Shares Outstanding | 108.23M |
| Shares Change (YoY) | +33.39% |
| Shares Change (QoQ) | +0.43% |
| Owned by Insiders (%) | 1.28% |
| Owned by Institutions (%) | n/a |
| Float | 106.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | -1.14 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -9.38 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.02
| Current Ratio | 0.02 |
| Quick Ratio | 0.02 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.23 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -22.35% |
| Return on Invested Capital (ROIC) | -181.35% |
| Return on Capital Employed (ROCE) | 17.87% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.00% in the last 52 weeks. The beta is 1.47, so Pharmadrug's price volatility has been higher than the market average.
| Beta (5Y) | 1.47 |
| 52-Week Price Change | -25.00% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.01 |
| Relative Strength Index (RSI) | 83.17 |
| Average Volume (20 Days) | 182,062 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -254,188 |
| Pretax Income | -389,922 |
| Net Income | -337,940 |
| EBITDA | -203,944 |
| EBIT | -254,188 |
| Earnings Per Share (EPS) | -0.00 |
Balance Sheet
The company has 17,716 in cash and 1.43 million in debt, giving a net cash position of -1.42 million or -0.01 per share.
| Cash & Cash Equivalents | 17,716 |
| Total Debt | 1.43M |
| Net Cash | -1.42M |
| Net Cash Per Share | -0.01 |
| Equity (Book Value) | -1.42M |
| Book Value Per Share | -0.01 |
| Working Capital | -1.96M |
Cash Flow
| Operating Cash Flow | -95,796 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Pharmadrug does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -33.39% |
| Shareholder Yield | -33.39% |
| Earnings Yield | -20.82% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 24, 2023. It was a reverse split with a ratio of 0.1428571.
| Last Split Date | Oct 24, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.1428571 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |